AUDIT OF DOWN-STAGING CHEMORADIATION FOR LOCALLY ADVANCED RECTAL CANCER DR J J NICOLL NORTH CUMBRIA UNIVERSITY HOSPITALS SEPTEMBER 2012.

Slides:

Advertisements

Similar presentations

Neoadjuvant therapy for Rectal cancer

Advertisements

IN THE NAME OF GOD. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy The American Journal.

Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.

North Tees University Hospital Audit of T1 Rectal Cancers September 2013 – August 2014 Nicola Maguire Teaching fellow General Surgery 12/09/2014.

Multimodality Therapy of Rectal Cancer Robert D. Madoff, MD University of Minnesota.

Rectal Cancer: A Complete Clinical Response…Now what?

JHSGR Neoadjuvant Therapy For Rectal Cancer Dr Chris TL Cheng Princess Margaret Hospital.

Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.

S Strong 1,2, NS Blencowe 1,2,T Fox 1, C Reid 3, T Crosby 4, H.Ford 5, J M Blazeby 1,2 1 School of Social and Community Medicine, Canynge Hall, University.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Colorectal Cancer An oncologists perspective

Abstract Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer A. Cercek, K.

Managing the patients experience of radical surgery with HIPEC for stage 4 colorectal disease Jackie Rodger Lead Colorectal Nurse Specialist Carol Baird.

DOWNSTAGING LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA (LAPC) WITH VASCULAR ENCASEMENT USING PERCUTANEOUS IRREVERSIBLE ELECTROPORATION (IRE) NARAYANAN,GOVINDARAJAN;

Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.

Management of Locally Advanced Rectal Cancer Joint Hospital Surgical Grand Round Pamela Youde Nethersole Eastern Hospital Dr. YH Ling 19 May 2007.

Colorectal Cancer Center Jena Introduction In Germany, there are currently approximately newly diagnosed patients with colorectal carcinoma.

Metastatic Spinal Cord Compression

Prospective Phase II Study of Preoperative Radiotherapy and Oral Capecitabine followed by Total Mesorectal Exicision (TME) in Locally Advanced Rectal Cancer.

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemo-radiotherapy for locally advanced rectal cancer: Long term results.

A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.

SURGERY FOR NSCLC GREG CHRISTODOULIDES MD, FACS, FCCP, FESTS

H Ariyaratne1,2, H Chesham2, J Pettingell2, K Sikora2, R Alonzi1,2

Should colonoscopy be performed one year out from colorectal cancer resection? Alexandra Kent, Philip Thompson, Prof Alan Horgan, Mr Paul Hainsworth Newcastle.

Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.

Chemoradiotherapy for Rectal cancer Dr. A. Sun Myint Lead Clinician GI Tumour Group Clatterbridge Centre for Oncology Association of Coloproctology of.

Dr Poonam Valand, Foundation Year Two Dr Anjan Dhar, Consultant Gastroenterologist COUNTY DURHAM AND DARLINGTON NHS FOUNDATION TRUST Early gastric cancer.

SPINDLE CELL SARCOMA OF BONE AN ASSESSMENT OF OUTCOME

Dr Mark Saunders Christie Hospital and Paterson Institute of Cancer Research “Anal cancer chemoradiotherapy”

The Impact of Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Patients with Carcinoma of the Rectum: NSABP R-04 1 Capecitabine.

The Colorectal Cancer Center Jena Gharbi A, Settmacher U. Department of General, Visceral and Vascular Surgery, Friedrich-Schiller-University Jena

CR07 results and informed patient consent David Sebag-Montefiore Leeds Cancer Centre.

TME trial TME radiotherapy 5 x 5 Gy TME alone randomisation n = 1861 resectable rectal carcinoma if CRM+: 50 GY.

Delivering clinical research to make patients, and the NHS, better OG neoadjuvant therapy Brachytherapy Stephen Falk dd/mm/yyyy.

Rectal Cancer: French Prodige Study: Best of ASCO, Beirut, July 2009 Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium.

“small” T3 short-term RT and TME “large” T3 long-term CRT and TME T4 long term CRT and TME Therefore: tailored treatment.

Accuracy of EUS in diagnosis of rectal cancer KKUH experience

Local recurrence after rectal cancer resection is strongly related to the plane of surgical (PoS) dissection and is further reduced by pre-operative short.

T Staging: Rectal cancer T1 invades submucosa T2 invades muscularis propria T3 invades subserosa or perirectal tissues T4 invades peritoneum, organs or.

Adjuvant chemotherapy in Rectal Cancer?. What is the evidence for adjuvant chemotherapy? Do patients achieving a pathological complete response need chemotherapy?

Stereotactic Ablative Body Radiotherapy for Non small cell lung cancer

EORTC Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM) Interim results of the EORTC.

Synchronous Metastasis on Staging/Surveillance CT chest abdomen & Pelvis + CEA + MRI Liver /PET-CT Synchronous Metastasis on Staging/Surveillance CT chest.

J. Lujan, G. Valero, Q. Hernandez, A. Sanchez, M.D. Frutos and P. Parrilla. British Journal of Surgery, September 2009.

Poster # 18, abstract # 4530 Long term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous.

Preliminary Results of the MRC CR07 / NCIC CO16 Randomized Trial Short course pre-op vs selective post-op chemo-RT for rectal cancer Local Recurrence after.

Dr Mark Saunders Christie Hospital and Paterson Institute of Cancer Research “ Rectal cancer radiotherapy – why do we give it and how do we do it?”

Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.

Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.

Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.

Multidisciplinary treatment of rectal cancer. Medical oncology Carlo Aschele E.O. Ospedali Galliera – Genova - Italy Carlo Aschele E.O. Ospedali Galliera.

Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer in the Elderly: A Population-Based Study in Ontario, Canada JOURNAL OF CLINICAL ONCOLOGY, VOLUME 30.

RECTAL CARCINOMA AND PREOPERATIVE MRI: USING A NATIONAL DATASET FOR REGIONAL AUDIT South West Cancer Intelligence Service J Weeks

Addition of Chemotherapy to Preoperative Radiotherapy Improves Outcomes in Rectal Cancer Slideset on: Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal.

SMDT SMDT SMDT Synchronous Metastasis on Staging/Surveillance

Brain imaging prior to lung cancer resection

Operative Approach and

Stage I Non Small Cell Lung Cancer (NSCLC): single centre comparison of outcome by treatment with surgery, conventional radiotherapy and stereotactic ablative.

1 Maidstone and Tunbridge Wells NHS Trust (Kent Oncology Centre)

Brain imaging prior to lung cancer resection

นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

IMRT delivery of preoperative, high dose radiotherapy to a large volume, with Simultaneous Integrated Boost (SIB) in retroperitoneal sarcomas: The Ottawa.

盧建璋, 陳鴻華, 李克釗, 胡萬祥, 張家駱, 蔡鎧隆, 林岳民, 鄭功全, 吳昆霖

What is the most appropriate therapy for a 50 year old patient with T3N+ rectal cancer and isolated resectable liver metastases? Systemic chemotherapy->chemoradiation->surgery.

Dr Jessica Jenkins Consultant Oncologist

Effect of Neoadjuvant Concurrent Chemoradiotherapy on Locally Advanced Middle and Low Rectal Cancer— A Propensity Score Matching Study 官泰全,林春吉,楊純豪,姜正愷,林宏鑫,藍苑慈,

National Oesophago-Gastric Cancer Audit 2018 Annual Report: Slide set

Presentation transcript:

AUDIT OF DOWN-STAGING CHEMORADIATION FOR LOCALLY ADVANCED RECTAL CANCER DR J J NICOLL NORTH CUMBRIA UNIVERSITY HOSPITALS SEPTEMBER 2012

STANDARD Aim is to achieve complete surgical resection with Circumferential Resection Margin (CRM) >1mm Success measured as number of CRM –ve resections and number of complete pathological responses (pCR) No nationally or internationally agreed standards. Meta-analysis of trials of pre-op CRT 2524 pts – pCR 10% Retrospective data on 677 pts from 6 UK centres – CRM –ve 70%; pCR 13% Denominator uncertain, different criteria for treatment. Aim to compare with data published in 2005 from Mount Vernon & “pooled series” from 7 UK centres.

METHODS RT database searched for patients receiving DXT (>23 fractions) and chemotherapy first registered pts identified as having radical chemoradiation (CRT) for rectal cancer. Database records examined – 12 patients were excluded because treatment was post-op, palliative or given for local recurrence. Remaining 64 pts. analysed for results of down-staging CRT.

TREATMENT 45GY/25# to Isocentre Capecitabine 825 mg/sq.m b.d throughout DXT weekends included. Restage (CT CAP & MRI) 6-10 weeks later.

RESULTS 41/64 (64%) underwent attempted resection. 23/64 (36%) had no surgery.

REASONS FOR NO RESECTION Metastatic disease on restaging CT scan 9 ( 5 were operable by MRI criteria) Not fit for surgery 3 Records not found 4 Patient refused surgery 2 Judged still inoperable on restaging MRI scan 4 Surgery attempted but failed 1 TOTAL 23

RESULTS OF RESECTION (resected patients only) CRM >1-10mm 19 CRM >10 mm 11 pCR 5 (12%) Total CRM -ve 35 (85%) Total CRM involved 6 (15%) CRM +ve – no recurrence 2 CRM +ve – local recurrence 4

RESULTS OR TREATMENT (ALL 64 PATIENTS) OPERATED41 (64%) R0 RESECTION35 (55%) pCR5 (8%)

COMPARISONS- OPERATED MOUNT VERNON % POOLED RESULTS 7 CENTRES % (RANGE 61-78%) NCUH64% (72% IF NO RESTAGING)

COMPARISONS – RO RESECTIONS MOUNT VERNON % (OF OPERATED) 65% (OF TOTAL) POOLED RESULTS 7 CENTRES % (OF OPERATED 63% (OF TOTAL RANGE %) NCUH85% (OF OPERATED) 55% (OF TOTAL)

COMPARISONS - pCR MOUNT VERNON % (OF OPERATED) 10% (OF TOTAL) POOLED RESULTS 7 CENTRES % (NO FURTHER DETAILS) NCUH12% (OF OPERATED) 8% (OF TOTAL)

NOTES Mount Vernon series (150 pts) did not repeat CT scan after CRT. 5 NCUH pts had mets on post-CRT CT scan and didn’t have surgery. No details of re-staging for “pooled series” (680 pts) MV series includes “borderline resectable” – no clear definition “Pooled series” included “locally advanced” – no definition given. We are not necessarily comparing like with like. Published series used FU/FA, not capecitabine. 4 records not found – treated as not having surgery.

CONCLUSIONS NCUH results are similar to two large UK series. Populations treated are similar but not strictly identical. NCUH standards are in line with other published results

ACTIONS Continue to offer down-staging CRT to patients identified at MDT to have threatened margins by MRI criteria. Offer suitable patients chance to participate in ARISTOTLE trial in the hope of improving results through the use of better chemotherapy.